You are here: Industry Insights > depression

News List

Janssen files nasal spray for depression pharmatimes
October 12, 2018
Janssen has submitted a marketing application to the European Medicines Agency (EMA) seeking approval of investigational nasal spray esketamine for the treatment of major depressive disorder.
New study to explore genetic links to depression and anxiety pharmatimes
September 20, 2018
Researchers are calling for 40,000 people with depression or anxiety in England to join an online study hoping to explore any genetic links to these conditions.
Parent-Child Interactive Intervention Cuts Depression drugs
August 06, 2018
An intervention targeting depression in very young children can be effective in community settings, according to a study published online June 20 in The American Journal of Psychiatry.
Efavirenz Doesn't Up Depression, Suicidal Ideation in HIV-Infected drugs
June 26, 2018
For persons living with HIV (PLHIV) in Uganda, use of efavirenz is not associated with increased risk of depression or suicidal ideation, according to a study published online June 26 in the Annals of Internal Medicine.
Johnson & Johnson's Potential Depression Blockbuster Esketamine Shows Promise in Phase II Study biospace
January 02, 2018
Janssen Research & Development a Johnson & Johnson company, has been working for several years on developing ketamine, a notable animal tranquilizer and drug-of-abuse with a street name of Special K, into a treatment for severe depression.
Takeda, Lundbeck plan U.S. test for depression app in latest beyond-the-pill foray fiercepharma
November 14, 2017
The pharma has teamed with Lundbeck and Advocate Health Care on a study that uses an app with a “conversational text interface” to track and measure patients’ experience on antidepressant therapies.
Magic mushrooms may 'reset' the brains of depressed patients worldpharmanews
October 17, 2017
Patients taking psilocybin to treat depression show reduced symptoms weeks after treatment following a 'reset' of their brain activity.
Depression affects nearly half of older adults in the UK pharmatimes
October 10, 2017
Nearly half of UK adults aged over 55 say they have experienced depression, according to a YouGov survey carried out for Age UK, highlighting the scale of the mental health challenge facing this age group.
Health risk assessments shed light on early predictors of depression worldpharmanews
April 12, 2017
A new research study supported by Johnson & Johnson Health and Wellness Solutions suggests that health risk assessments (HRAs) can help predict depression in segments of the population who may not be routinely screened in traditional healthcare settings.
Allergan to move Botox into PhIII for depression pharmatimes
April 07, 2017
Allergan has reported mixed top-line data from a mid-stage trial testing Botox as a treatment for major depressive...

Previous page 1 2 3 4 5 6 7 8 9 10 Next page